L-019
Lamotrigine solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
等级
certified reference material
质量水平
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
储存温度
−20°C
SMILES字符串
Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl
InChI
1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
InChI key
PYZRQGJRPPTADH-UHFFFAOYSA-N
基因信息
一般描述
Lamotrigine is an anticonvulsant approved for treatment of epilepsy and bipolar disorder. Sold under the trade name Lamictal®, this phenyltriazine analog also is used off-label for treatment of clinical depression. This Snap-N-Spike® Reference Solution is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications such as forensic analysis and clinical toxicology.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Lamictal is a registered trademark of GlaxoSmithKline LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Chaitali Ghosh et al.
Epilepsia, 54(9), 1562-1570 (2013-07-20)
Brain drug bioavailability is regulated by the blood-brain barrier (BBB). It was recently suggested that cytochrome P450 (CYP) enzymes could act in concert with multidrug transporter proteins to regulate drug penetration and distribution into the diseased brain. The possibility that
Crystal T Clark et al.
The American journal of psychiatry, 170(11), 1240-1247 (2013-11-05)
Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder. The authors present new data on serial serum levels of lamotrigine in pregnant patients on lamotrigine monotherapy. They also review the epilepsy
Philip J Wiffen et al.
The Cochrane database of systematic reviews, (2)(2), CD006044-CD006044 (2011-02-18)
This is an update of the original Cochrane review published in Issue 2, 2007. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This updated review adds five new additional studies looking
Jacqueline A French et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 9(1), 176-184 (2011-12-06)
The efficacy and safety of lamotrigine extended-release tablets (LTG XR) as monotherapy for partial seizures were evaluated using the conversion-to-monotherapy design, and historical data as the control. This methodology was recently approved by the United States Food and Drug Administration
Jennifer G Reid et al.
The Journal of clinical psychiatry, 74(7), 675-684 (2013-08-16)
Owing to the prevalence of medication side effects and treatment resistance, prescribers often consider off-label uses of US Food and Drug Administration (FDA)-approved agents for the treatment of persistent symptoms. The authors review the available literature on the FDA-approved and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持